Inhibitory effect of antituberculosis drugs on human cytochrome P450-mediated activities

Journal of Pharmacological Sciences

Volumn 96, Issue 3, 2004, Pages 293-300

  Nishimura, Yuki ^a   Kurata, Norimitsu ^a   Sakurai, Eriko ^a   Yasuhara, Hajime ^a  

^a SHOWA UNIVERSITY   (Japan)

Author keywords

Antituberculosis drug; Cytochrome P 450; Drug interaction; Human liver microsome; Inhibition

Indexed keywords

BUFURALOL; CHLORZOXAZONE; CYTOCHROME P450; CYTOCHROME P450 1A2; CYTOCHROME P450 2A6; CYTOCHROME P450 2C19; CYTOCHROME P450 2C9; CYTOCHROME P450 2E1; CYTOCHROME P450 3A; ETHIONAMIDE; ETHOXYRESORUFIN; ISONIAZID; MEPHENYTOIN; MIDAZOLAM; PYRAZINAMIDE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE; TUBERCULOSTATIC AGENT; WARFARIN;

ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DILUTION; DRUG CROSS REACTIVITY; DRUG HYDROXYLATION; DRUG METABOLISM; ENZYME INHIBITION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; INCUBATION TIME; LIVER MICROSOME; SPECTROFLUOROMETRY;

EID: 10944240204     PISSN: 13478613     EISSN: None     Source Type: Journal    
DOI: 10.1254/jphs.FP0040296     Document Type: Article

References (32)

1. Zhou HH, Anthony LB, Wood AJ, Wilkinson GR. Induction of polymorphic 4′-hydroxylation of S-mephenytoin by rifampicin. Br J Clin Pharamacol. 1990;30:471-475.
2. Eichelbaum M, Mineshita S, Onnhaus EE, Zekorn C. The influence of enzyme induction on polymorphic sparteine oxidation. Br J Clin Phramaocol. 1986;22:49-53.
3. Kolars JC, Schmiedlin-Ren P, Schuetz ID, Fang C, Watkins PB. Identification of rifampin-inducible P450 IIIA4 (CYP3A4) in human small bowel enterocytes. J Clin Invest. 1992;90:1871-1878.
4. Herbert MF, Roberts JP, Prueksaritanont T, Benet LZ. Bioavailability of cyclosporine with concomitant rifampin administration is markedly less than predicted by hepatic enzyme induction. Clin Pharamacol Ther. 1992;52:453-457.
5. Venkatesan K. Phramacokinetic drug interactions with rifampicin. Clin Pharmacokinet. 1992;22:47-65.
6. Murphy R, Swartz R, Watkins PB. Severe acetaminophen toxicity in a patient receiving isoniazid. Ann Intern Med. 1990;113:799-800.
7. Valsalan VC, Cooper GL. Carbamazepine intoxication caused by interaction with isoniazid. Br Med J (Clin Res Ed.). 1982;285:261-262.
8. Muray FJ. Outbreak of unexpected reactions among epileptics taking isoniazid. Am Rev Respir Dis. 1962;86:729-732.
9. Hoglund P, Nillson LG, Paulsen O. Interaction between isoniazid and theophylline. Eur J Respir Dis. 1987;70:110-116.
10. Rosenthal AR, Self TH, Baker ED, Linden RA. Interaction of isoniazid and warfarin. JAMA. 1977;238:2177.
11. Self TH, Chrisman CR, Baciewicz AM, Bronze MS. Isoniazid drug and food interactions. Am J Med Sci. 1999;317:304-311.
12. Maukkassah SF, Bidlack WF, Yang WCT. Mechanism of the inhibitory action of isoniazid on microsomal drug metabolism. Biochem Pharmacol. 1981;30:1651-1658.
13. Desta Z, Soukhova NV, Flockhart DA. Inhibition of cytochrome P450 (P450) isoforms by isoniazid: potent inhibition of CYP2C19 and CYP3A. Antimicrob Agents Chemother. 2001; 45:382-392.
14. Wen X, Wang J-S, Neuvonen PJ, Backman JT. Isoniazid is a mechanism-based inhibitor of cytochrome P450 1A2, 2A6, 2C19 and 3A4 isoforms in human liver microsomes. Eur J Clin Phramacol. 2002;57:799-804.
15. Sandyk R. Phenytoin toxicity induced by antituberculosis drugs. S Afr Med J. 1982;61:382.
16. Miners JO, Birkett DJ. Cytochrome P4502C9: an enzyme of major importance in drug metabolism. Br J Clin Pharmacol. 1988;45:525-538.
17. Bjpai M, Roskos LK, Shen DD, Levy RH. Roles of cytochrome P4502C9 and cytochrome 2C19 in the streoseloective metabolism of phenytoin to its major metabolite. Drug Metab Dispos. 1996;24:1401-1403.
18. Facino RM, Carini M. The inhibitory effect of pyrazinamide on microsomal monooxygenase activities is related to the binding to reduced cytochrome P-450. Pharmacol Res Commun. 1980;12: 523-537.
19. Williams FM, Mutch E, Woodhouse KW, Lambert D, Rawlins MD. Ethoxyresorufin O-deethylation by human liver microsomes. Br J Clin Pharmacol. 1986;22:263-268.
20. Shinjari T, Torinwall U, Darnerud PO. Inducution of 7-ethoxyresorufin O-deethylase (EROD) activity in mice fetuses by the PCB-congener 3,3′-4,4′-tetrachlorobiphenyl. Xenobiotica. 1993; 23:107-114.
21. Chiba K, Manabe K, Kobayashi K, Takayama Y, Tani M, Ishizaki T. Development and preliminary application of a simple assay of S-mephenytoin 4-hydroxylase activity in human liver microsomes. Eur J Clin Pharmacol. 1993;44:559-562.
22. Kronbach T, Mathys D, Gut J, Catin T, Meyer UA. High-performance liquid Chromatographic assays for bufuralol 1′-hydroxylase, debrisoquine 4-hydroxylase, and dextromethorphan O-demethylase in microsomes and purified cytochrome P-450 isozymes of human liver. Anal Biochem. 1987;162:24-32.
23. Kurata N, Nishimura Y, Iwase M, Fischer NE, Tang BK, Inaba T, et al. Trimethadione metabolism by human liver cytochrome P450: evidence for the involvement of CYP2E1. Xenobiotica. 1998;28:1041-1047.
24. Wrighton SA, Ring BJ. Inhibition of human CYP3A catalyzed 1′-hydroxymidazolam formation by ketoconazole, nifedipine, erythromycin, cimetidine, and nizatidine. Pharmaceut Res. 1994;11:921-924.
25. Lesca P, Lecointe P, Paoletti C, Mansuy D. Ellipticines as potent inhibitors of aryl hydrocarbon hydroxylase: their binding to microsomal cytochromes p450 and protective effect against benzo(a)pyrene mutagenicity. Biochem Pharmacol. 1978;27: 1203-1209.
26. Raucy JL, Lasker JM, Lieber CS, Black M. Acetaminophen activation by human liver cytochromes P450 IIE1 and P450 IA2. Arch Biochem Biophys. 1989;271:270-283.
27. Peter R, Böcker R, Beaune PH, Iwasaki M, Guengerich FP, Yang CS. Hydroxylation of chlorzoxazone as a specific probe for human liver cytochrome P450 IIE1. Chem Res Toxicol. 1990;3:566-573.
28. Thummel KE, Kharasch ED, Podoll T, Kunze K. Human liver microsomal enflurane defluorination catalyzed by cytochrome P450 2E1. Drug Metab Dispos. 1993;21:350-357.
29. Zand R, Nelson SD, Slattery JT, Thummel KE, Kalhorn TF, Adams SP, et al. Inhibition and induction of cytochrome P4502E1-catalyzed oxidation by isoniazid in humans. Clin Pharmacol Ther. 1993;54:142-149.
30. Chien JY, Peter RM, Nolan CM, Wartell C, Slattery JT, Nelson SD, et al. Influence of polymorphic N-acetyltransferase phenotype on the inhibition and induction of acetaminophen bioactivation with long-term isoniazid. Clin Pharmacol Ther. 1997;61:24-34.
31. O'Shea D, Kim RB, Wilkinson GR. Modulation of CYP2E1 activity by isoniazid in rapid and slow N-acetylators. Br J Clin Phramacol. 1997;43:99-103.
32. Jones DR, Hall SD. Mechanism-based inhibition of human cytochrome P450: in vitro kinetics and in vitro-in vivo correlations. In: Rodrigues AD, editor. Drug-drug interactions. 2nd. Drugs and the pharmaceutical sciences 116. New York: Marcel Dekker, Inc; 2001. p. 387-413.